Detalhe da pesquisa
1.
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Lancet Oncol
; 24(10): 1134-1146, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797632
2.
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
Nat Med
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38750351